Theme watch · maturing
Precision biotech stocks to watch · August 2026.
As of 25 August 2026
Milestone-and-royalty flywheel turned visible: Q2 revenue $13.415M vs $4.693M consensus (2026-08-06) plus a Lilly ion-channel deal worth up to…
Single-asset binary, now inside the guided window: Amylyx reaffirmed on 2026-08-06 that Phase 3 LUCIDITY topline for avexitide in post-bariatric…
Post-dilution CNS microcap re-firing with the psychedelic cohort (ATAI, CMPS all moving 2026-07-16) after a June social-velocity blowoff and a…
Post-print launch-ramp narrative still accelerating on fundamentals — Q2 net sales $28.5M vs $12.7M consensus (2026-08-12), NTAP effective…
Wet-AMD one-and-done durability narrative accelerating on the 2026-07-18 PRISM 2-year data (78% injection-burden reduction, 2.7 vs 12.0 projected,…
Margin-inflection re-rating still paying: Q2 (2026-08-05) printed $84.1M revenue (+21% YoY) and a third straight positive adjusted EBITDA quarter,…
Q2 on 2026-08-13 resolved the binary upward — product sales $37.6M vs $27.1M consensus, FY26 guide to >$145M from >$120M — and four brokers raised…
Single-asset schizophrenia binary where the sell-side frame flipped above the tape: BMO $54 (2026-08-12), Stifel $53 (08-13), Clear Street $69…
Precision-psychiatry TRD re-rate broke to new highs on a low-information 2026-08-12 Q2 print (EPS -$0.65 vs -$0.73 est) and two same-week target…
Deal-spread endgame: HSR expired 2026-08-18 (SC 14D9/A filed 2026-08-19), leaving only the >50% minimum tender before argenx's $77.00 all-cash…
"3-mo price move" is the stock's market price change, not a FrontierPicks return. The "3-mo price move" column is one of the three inputs to that score, weighted 20% — not the ranking itself, so rows do not descend in it. A dash means the name did not place in this week’s top-50 momentum scan, so it has no published 3-month figure.
How this page is built
These are the names FrontierPicks covers in the precision biotech stocks cluster — each with a dated research dossier. Names on the momentum board rank first by a composite momentum score — 1-month price trend 50%, 3-month trend 20% and acceleration 30% — computed arithmetically from daily closes, then the rest of the covered roster by conviction tier. Cluster membership is assigned by a frontier model, currently read as maturing.
Questions
- What precision biotech stocks does FrontierPicks cover?
- As of 25 August 2026, the precision biotech stocks FrontierPicks tracks are led by OABI, AMLX, HELP, OMER, each with a dated research dossier. Names on the momentum board rank first by composite momentum score, then the rest of the covered roster by conviction tier; this is research, not a recommendation.
- Is the precision biotech stocks theme accelerating or slowing?
- The FrontierPicks model reads this cluster as maturing as of 25 August 2026. Still working on sell-side support — AMLX priced an upsized $500M offering at $35.50 (2026-08-20) into PT raises from Mizuho ($42) and Guggenheim ($55) on 08-19, B of A initiated ALVO at Buy/$7 (08-24), HC Wainwright raised LBRX to $60 (08-24). Momentum is decaying underneath: HELP 1m 70.5 vs 3m 177.6, AMLX 106.6 vs 180.1, ETON 51.4 vs 97.9, and several members (OABI, OMER, ETON, FDMT) carry no headline at all this week.
- How does FrontierPicks rank precision biotech stocks?
- Every name links to its dated research dossier. Names on the momentum board rank first by composite momentum score, then the rest of the covered roster by conviction tier. Methodology is open; this is research, not advice.
Related
As of 25 August 2026 · research, not advice.